Cerebral Autoregulation and COVID-19 (CA-COVID)
COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Pneumonia
About this trial
This is an interventional diagnostic trial for COVID-19 Acute Respiratory Distress Syndrome focused on measuring COVID-19, Cerebrovascular circulation, Spectroscopy, Near-Infrared
Eligibility Criteria
Inclusion Criteria:
- Admission to ICU and endotracheal intubation/mechanical ventilation for severe COVID-19 infection
Exclusion Criteria:
- Age <18 years
- Pregnancy
- Patients with a terminal underlying disease who are unlikely to survive until discharge from the hospital
- Patients with acquired immunodeficiency and ("pre-COVID") lymphocyte Cluster Differentiation 4+ count <50 / μL
- Patients with COVID-19 who have been transferred from another hospital
- Patients with a history of allergic reaction
- Use of prone position to facilitate mechanical ventilation
- Absence of signed informed consent from a first degree relative
Sites / Locations
- Department of Intensive Care Medicine Evaggelismos General HospitalRecruiting
Arms of the Study
Arm 1
Experimental
ICU patients with COVID-19
NIRS monitoring will be performed for approximately 90 minutes at 2 mean blood pressure levels (MAP, ie 65-70 mmHg and 95-100 mmHg) within 12-48 hours and 60-84 hours after admission to the ICU for severe COVID-19 infection. Autoregulation will be assessed using Tissue Oxygenation Index values and mean arterial pressure values in a regression analysis and will be considered sufficient if the relative Pearson correlation coefficient is less than 0.3. Cerebral blood flow will be assessed by blood flow index determination after intravenous infusion of 5 mg indocyanine.